NCT02775903: A reported trial by Celgene
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02775903 |
|---|---|
| Title | A Randomized, Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (>= 65 Years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | June 3, 2016 |
| Completion date | Dec. 31, 2018 |
| Required reporting date | Dec. 31, 2019, midnight |
| Actual reporting date | Oct. 30, 2019 |
| Date last checked at ClinicalTrials.gov | Sept. 4, 2025 |
| Days late | None |